Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing

PURPOSE: To investigate the HER2 status and clinicopathological features in invasive breast cancer with HER2 ≥4.0 and <6.0, which has always been controversial. METHODS: Forty breast cancer cases with HER2 ≥4.0 and <6.0 by fluorescence in situ hybridization (FISH) were collected and classified...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Qianming, Lv, Hong, Bao, Longlong, Yang, Yu, Zhang, Xin, Chang, Heng, Xue, Tian, Ren, Min, Zhu, Xiaoli, Zhou, Xiaoyan, Yang, Wentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406110/
https://www.ncbi.nlm.nih.gov/pubmed/37554155
http://dx.doi.org/10.2147/BCTT.S420738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406110/
https://www.ncbi.nlm.nih.gov/pubmed/37554155
http://dx.doi.org/10.2147/BCTT.S420738

Ejemplares similares